Clinical factors in the selection of patients for first-line immunotherapy of lung cancer VJOncology 2:43 7 years ago 164 Скачать Далее
Immunotherapy/Checkpoint Inhibitor, Targeted Immunotherapy Drugs 5/2/18 Mary Greeley Medical Center 52:27 6 years ago 1 374 Скачать Далее
Dr. Amin on Toxicities With Immunotherapy/TKI Combinations in RCC OncLive 2:16 5 years ago 240 Скачать Далее
Selecting EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Lung Cancer Targeted Oncology 0:52 4 years ago 441 Скачать Далее
Factors to Consider in Choosing ALK TKIs in Frontline Setting OncLive 7:38 5 years ago 41 Скачать Далее
Immunotherapy: Moving beyond PD1 and PDL1 inhibitors HMP Education 23:02 6 years ago 7 174 Скачать Далее
Clinical Recommendations for Choosing TKIs or Immunotherapy for mRCC PracticeUpdate 6:34 3 years ago 11 Скачать Далее
Selecting patients for immunotherapy based on driver mutations VJOncology 6:26 2 years ago 72 Скачать Далее
Patient Selection for Checkpoint Inhibitor Therapy and Assessing Response OncLive 4:26 8 years ago 136 Скачать Далее
The Role of Tyrosine Kinase Inhibitors and mTOR Inhibitors Kidney Cancer 41:21 9 years ago 4 284 Скачать Далее
NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment HMP Education 37:23 5 years ago 7 357 Скачать Далее
Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agents HMP Education 25:26 6 years ago 1 240 Скачать Далее
CAMILLA: Combining a VEGF TKI with immune checkpoint inhibitors for GE and GI cancer VJOncology 1:30 2 years ago 125 Скачать Далее